Publications
Showing all 20 journal articles & 1 books available
Journal Articles
2013
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikaruddin JJ, Mulford D, Chen R, Bechelli J, Roswell K, Minhajuddin M, Jordan CT, Phillips Gl 2nd. "A phase I study of decitabine and rapamycin in relapsed/refractory AML". Leukemia Research. 2013; 37(12): 1662-7.
2011
Milner LA; Becker MW; Bernstein SH; Bruckner L; Friedberg JW; Holland GA; Ifthikharuddin JJ; LIesveld JL; Mathes EJ; Mechel HL; Mullen CA; Sasson T; Phillips GL 2nd. "Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease". Am J Hematology. 2011; 86(8): 712-714.
2011
Liesveld JL; Rosell KE; Bechelli J; Lu C; Messina P; Mulford D; Ifthikharuddin JJ; Jordan CT; Phillips GL 2nd. "Proteasome inhibition in myelodysplastic syndromes and acute myelogeneous leukemia cell lines". Cancer Invest. 2011; 29(7): 438-450.
2008
Walker,AR; Komrokji, RS; Ifthikharuddin, JJ; Messina, P; Mulford, D; Becker, M; Friedberg, J; Oliva, J; Phillips, G; Liesveld, JL; Abboud, C. "Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (g-CSF) (CLAG regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML." Leukemia Research. 2008; 12(32): 1830-1836.
2008
Phillips GL 2nd; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW. "A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection". Leuk Res. 2008; 32(12): 1830-1836.
4/1/2006
Zand MS, Vo T, Pellegrin T, Felgar R, Liesveld JL, Ifthikharuddin JJ, Abboud CN, Sanz I, Huggins J. "Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin." Blood.. 2006 Apr 1; 107(7):2895-903. Epub 2005 Dec 20.
2005
Liesveld,J. L.; Abboud,C. N.; Bernstein,S. S.; Friedberg,J.; Ifthikharuddin,J. J.; Constine,L. S.; Kaplan,K. L.; Wedow,L. A.; Nichols,D. D.; Oliva,J.; Etter,M.; Phillips,G. L. II;. "Extracorporeal photopheresis, Pentostatin and TBI for reduced intensity preparation: Adaptation of the Tufts experience at a single transplant center." Blood. 2005; 106(11): 440B.
2005
Dib, E.; Ifthikharuddin, J.J.; Scott, G. A.; Partilo, S.R. "Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy." Leukemia Research. 2005; 20: 233-234.
12/2004
Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH. "Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report." Seminars in oncology.. 2004 Dec; 31(6 Suppl 18):59-61.
8/2004
Komrokji R, Ifthikharuddin JJ, Felgar RE, Abboud CN, Wedow LA, Connaughton A, Bennett JM. "Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: case report and literature review." American journal of hematology.. 2004 Aug; 76(4):389-94.
2002
Liesveld,J. L.; Nichols,D.; Ifthikharuddin,J. J.; Lancet,J. E.; Abboud,C. N.;. "Use of imatinib mesylate in CML patients autografted in the pre-imatinib era: A single center experience." Blood. 2002; 100(11): 473B.
2002
Fu SQ, Abboud CN, Brennan JK, Ifthikharuddin JJ, Nichols D, Liesveld JL. "Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation." Blood cells, molecules & diseases.. 2002 28(3):315-21.
2002
Liesveld JL, Abboud CN, Ifthikharuddin JJ, Lancet JE, Wedow LA, Oliva J, Stamm CG, Nichols D. "Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients." Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.. 2002 8(12):662-5.
2001
Shah,P. K.; Ifthikharuddin,J. J.; Mintz,M.; Felgar,R.; Liesveld,J.; Abboud,C.;. "2-Chlorodeoxyadenosine (2-CDA) with weekly rituximab and granulocyte-macrophage stimulating factor (GM-CSF): A highly effective regimen for advanced B-cell lymphoproliferative disorders (BLPD)." Blood. 2001; 98(11): 249b.
2001
Shah, P.; Ifthikharuddin, J.J.; Mintz, M.; Felgar, R.; Liesveld, J.; Abboud, C;. "Rituximab and cladribine (2-CDA): In-vivo synergistic activity in B-cell lymphoproliferative disorders (BLPD) expressing the CD20 antigen." Proc. ASCO. 2001; 20(2): 228b.
10/2000
Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, Ryan CK, Sahasrabudhe DM. "CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab." American journal of hematology.. 2000 Oct; 65(2):171-3.
1999
Ifthikharuddin,J. J.; Mieles,L. A.; Rosenblatt,J. D.; Ryan,C. K.; Sahasrabudhe,D. M.;. "CD-20 expression in post-transplant lymphoproliferative disorders (PTLD): Treatment with Rituximab" . Blood. 1999; 94(1): 248b.
3/1997
Ifthikharuddin JJ, Janas J, Phatak PD. "Isolated splenic blastic transformation of idiopathic myelofibrosis and response to splenectomy." Leukemia research.. 1997 Mar; 21(3):255-7.
9/1994
Lim SH, Ifthikharuddin JJ. "Autoimmune thrombocytopenic purpura complicating lymphoproliferative disorders." Leukemia & lymphoma.. 1994 Sep; 15(1-2):61-4.
1992
Ifthikharuddin, J.J.; Holmes, J.A. "Clostridium perfringens septicaemia and massive intravascular haemolysis as a terminal complication of autologous bone marrow transplant." Clinical & Laboratory Haematology. 1992; 14(2): 159-61.